Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FEMY NASDAQ:MDAI NASDAQ:POCI NASDAQ:SLNO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFEMYFemasys$4.18-12.6%$7.69$4.02▼$22.20$14.43M-2.23123,734 shs89,814 shsMDAISpectral AI$1.82-2.2%$2.02$1.18▼$3.21$59.19M1.151.07 million shs365,368 shsPOCIPrecision Optics$5.89+2.1%$4.77$3.55▼$6.15$63.15M0.3273,174 shs59,084 shsSLNOSoleno Therapeutics$53.01$47.81$29.43▼$90.32$2.76B-2.221.75 million shsN/A The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFEMYFemasys+1.06%-33.09%-36.62%-58.07%-71.88%MDAISpectral AI+1.64%-7.46%-13.49%+40.91%-9.27%POCIPrecision Optics+2.12%+4.34%+27.09%+30.90%+18.97%SLNOSoleno Therapeutics0.00%0.00%+0.15%+57.02%-33.03%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFEMYFemasys$4.18-12.6%$7.69$4.02▼$22.20$14.43M-2.23123,734 shs89,814 shsMDAISpectral AI$1.82-2.2%$2.02$1.18▼$3.21$59.19M1.151.07 million shs365,368 shsPOCIPrecision Optics$5.89+2.1%$4.77$3.55▼$6.15$63.15M0.3273,174 shs59,084 shsSLNOSoleno Therapeutics$53.01$47.81$29.43▼$90.32$2.76B-2.221.75 million shsN/A The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFEMYFemasys+1.06%-33.09%-36.62%-58.07%-71.88%MDAISpectral AI+1.64%-7.46%-13.49%+40.91%-9.27%POCIPrecision Optics+2.12%+4.34%+27.09%+30.90%+18.97%SLNOSoleno Therapeutics0.00%0.00%+0.15%+57.02%-33.03%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFEMYFemasys 2.50Moderate Buy$106.672,451.83% UpsideMDAISpectral AI 2.00Hold$4.00119.78% UpsidePOCIPrecision Optics 1.00SellN/AN/ASLNOSoleno Therapeutics 2.08Hold$76.6744.63% UpsideCurrent Analyst Ratings BreakdownLatest FEMY, SLNO, POCI, and MDAI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2026POCIPrecision Optics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/3/2026FEMYFemasys Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/26/2026MDAISpectral AI BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$3.00 ➝ $4.005/21/2026MDAISpectral AI Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/19/2026SLNOSoleno Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral5/18/2026FEMYFemasys Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/11/2026SLNOSoleno Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/6/2026MDAISpectral AI Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/1/2026FEMYFemasys Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/17/2026SLNOSoleno Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight ➝ Equal Weight$110.00 ➝ $53.004/17/2026SLNOSoleno Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$110.00 ➝ $53.00(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFEMYFemasys$2.38M5.31N/AN/A$2.01 per share2.08MDAISpectral AI$19.65M2.95N/AN/A($0.19) per share-9.58POCIPrecision Optics$28.94M2.23N/AN/A$1.60 per share3.68SLNOSoleno Therapeutics$285.01M9.69$0.43 per share124.10$9.51 per share5.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFEMYFemasys-$18.63M-$5.40N/AN/AN/A-521.97%-258.08%-73.72%8/12/2026 (Estimated)MDAISpectral AI-$7.57M-$0.53N/AN/AN/A-85.58%N/A-72.97%8/11/2026 (Estimated)POCIPrecision Optics-$5.78M-$0.63N/AN/AN/A-17.03%-37.47%-19.96%N/ASLNOSoleno Therapeutics$20.89M$1.7729.959.89N/A33.70%22.85%18.25%8/5/2026 (Estimated)Latest FEMY, SLNO, POCI, and MDAI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q3 2026POCIPrecision OpticsN/A-$0.01N/A-$0.01N/A$8.71 million5/12/2026Q1 2026MDAISpectral AI-$0.11-$0.11N/A-$0.11$4.13 million$3.99 million5/8/2026Q1 2026FEMYFemasys-$1.3334$0.0980+$1.4314N/A$0.77 million$0.42 million3/31/2026Q4 2025FEMYFemasys-$1.6666-$0.20+$1.4666-$0.01$1.06 million$0.81 million3/24/2026Q4 2025MDAISpectral AI-$0.1267$0.02+$0.1467$0.02$2.91 million$3.85 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthFEMYFemasysN/AN/AN/AN/AN/AMDAISpectral AIN/AN/AN/AN/AN/APOCIPrecision OpticsN/AN/AN/AN/AN/ASLNOSoleno TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFEMYFemasys0.533.911.98MDAISpectral AIN/A0.750.71POCIPrecision Optics0.042.101.74SLNOSoleno Therapeutics0.105.625.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFEMYFemasys65.27%MDAISpectral AI67.08%POCIPrecision Optics13.71%SLNOSoleno Therapeutics97.42%Insider OwnershipCompanyInsider OwnershipFEMYFemasys7.55%MDAISpectral AI13.70%POCIPrecision Optics14.40%SLNOSoleno Therapeutics6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFEMYFemasys303.02 million2.79 millionNot OptionableMDAISpectral AI8331.82 million27.46 millionNot OptionablePOCIPrecision Optics8010.95 million9.37 millionNot OptionableSLNOSoleno Therapeutics3052.12 million48.78 millionOptionableFEMY, SLNO, POCI, and MDAI HeadlinesRecent News About These CompaniesSLNO 8-DAY DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Securities Class Action Alleging Hyperphagia Drug Launch Disruptions - Hagens BermanMay 11, 2026 | prnewswire.comSoleno Merger With Neurocrine Puts Profitability And Valuation In FocusMay 10, 2026 | finance.yahoo.comSOLENO DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLNOMay 5, 2026 | newsfilecorp.comNSOLENO DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLNOMay 5, 2026 | newsfilecorp.comNINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – SLNOMay 5, 2026 | globenewswire.comSLNO DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Today's Lead Plaintiff Deadline in Securities Class ActionMay 5, 2026 | prnewswire.comDEADLINE ALERT for EOSE, SLNO, and NKTR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of ShareholdersMay 5, 2026 | globenewswire.comSLNO Shareholder Alert: Soleno Therapeutics, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law FirmMay 5, 2026 | prnewswire.comPortnoy Law Firm Announces Class Action on Behalf of Soleno Therapeutics, Inc. InvestorsMay 5, 2026 | globenewswire.comSOLENO THERAPEUTICS DEADLINE TOMORROW: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLNOMay 4, 2026 | newsfilecorp.comNSOLENO THERAPEUTICS CLASS ACTION DEADLINE TOMORROW: Bragar Eagel & Squire, P.C. Urges Soleno Therapeutics, Inc. Investors with Significant Losses to Contact the Firm Before May 5th Lead Plaintiff DeadlineMay 4, 2026 | globenewswire.comDeadline Soon: Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz About Securities Fraud LawsuitMay 4, 2026 | tmcnet.comSOLENO THERAPEUTICS DEADLINE TOMORROW: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLNOMay 4, 2026 | globenewswire.comSLNO INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026May 4, 2026 | newsfilecorp.comNBronstein, Gewirtz & Grossman LLC Urges Soleno Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmMay 4, 2026 | globenewswire.comSLNO Deadline: SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud LawsuitMay 4, 2026 | prnewswire.comSLNO SHAREHOLDER NOTICE: Hagens Berman Alerts Soleno (SLNO) Investors to Pending Securities Fraud Class Action and Upcoming May 5th Lead Plaintiff DeadlineMay 4, 2026 | globenewswire.comSoleno Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SLNOMay 4, 2026 | prnewswire.comSLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmMay 4, 2026 | prnewswire.comSOLENO THERAPEUTICS DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLNOMay 3, 2026 | newsfilecorp.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFEMY, SLNO, POCI, and MDAI Company DescriptionsFemasys NASDAQ:FEMY$4.18 -0.60 (-12.55%) Closing price 04:00 PM EasternExtended Trading$4.38 +0.20 (+4.67%) As of 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.Spectral AI NASDAQ:MDAI$1.82 -0.04 (-2.15%) Closing price 04:00 PM EasternExtended Trading$1.84 +0.02 (+1.15%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Spectral AI, Inc., an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView System, a predictive analytics platform integrated with the predictive AI-Burn, which combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential and offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention; and DeepView SnapShot M, a handheld, portable, and wireless diagnostic tool, that provides a potential enhanced and expanded use for the government and emergency care, first responders, and potentially home health care professionals. The company is headquartered in Dallas, Texas.Precision Optics NASDAQ:POCI$5.89 +0.12 (+2.08%) Closing price 04:00 PM EasternExtended Trading$5.87 -0.02 (-0.34%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Precision Optics Corporation, Inc. designs, develops, manufactures, and sells specialized optical and illumination systems and related components primarily in the United States and the European Economic Area. It offers medical instrumentation products, including endoscopes and endocouplers, as well as other custom imaging and illumination products, such as Microprecision lenses and micro medical cameras, and 3D endoscopes for use in minimally invasive surgical procedures by hospitals and physicians. The company also provides components and assemblies for industrial and military use. It markets its products to medical device companies. The company was incorporated in 1982 and is based in Gardner, Massachusetts.Soleno Therapeutics NASDAQ:SLNOSoleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
